Infectious diseases caused by viral or bacterial pathogens are a major cause of death and morbidity worldwide and constitute an ever growing medical need. We are focusing on discovery, research and development of new anti-infective agents, targeting both the pathogen as well as the host immune defences. In this, we build on an industry-leading technology platform and on a rich legacy of research in this field, which produced some outstanding therapeutics in hepatitis B, influenza and multi-drug resistant bacterial infections.
Dicerna – research collaboration and licensing agreement to develop siRNA therapies for the treatment of chronic hepatitis B virus (HBV) infection
Patrick Schleck, Head of Immunology & Infectious Diseases, Pharma Partnering
Karl Yen, Search & Evaluation Lead Immunology and Infectious Diseases, Pharma Partnering